Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

13.94 +0.39 (+2.88%)
Streaming Delayed Price Updated: 11:37 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 343,917
Open 13.51
Bid (Size) 13.83 (200)
Ask (Size) 13.94 (600)
Prev. Close 13.55
Today's Range 13.17 - 13.94
52wk Range 2.210 - 19.50
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance
Phathom Pharma's Q3 2025 earnings beat expectations. Revenue hit $49.5M, and its EPS loss narrowed to $0.15. The company also raised its full-year 2025 revenue guidance. 
Via Chartmill
Topics Earnings

Performance

YTD
+90.2%
+90.2%
1 Month
+14.2%
+14.2%
3 Month
+61.3%
+61.3%
6 Month
+440.3%
+440.3%
1 Year
-26.4%
-26.4%

More News

Read More
Earnings Scheduled For October 30, 2025
Via Benzinga
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
Via Benzinga
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom (PHAT) Q2 Revenue Jumps 441%
Via The Motley Fool
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket
Via Chartmill
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
From Phathom Pharmaceuticals
Via GlobeNewswire
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
Via Benzinga
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna
Via Benzinga
Which stocks are moving on Friday?
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
From Phathom Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 13.94
When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 11/03/25 11:37 AM ET
What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 607.98M
How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
Phathom Pharmaceuticals, Inc. - Common Stock has 608M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.